Trial Profile
A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Tianjin CanSino Biotechnology
- 28 Oct 2022 Status changed from recruiting to completed.
- 22 Sep 2021 Results assessing safety and immunogenicity results of Ad5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants, published in the Clinical Infectious Diseases
- 01 Oct 2020 New trial record